Comment on

• Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection.

  Landemaine A, Petitcollin A, Brochard C, Miard C, Dewitte M, Le Balc'h E, Grainville T, Bellissant E, Siproudhis L, Bouguen G. Landemaine A, et al. Clin Gastroenterol Hepatol. 2021 Feb;19(2):288-295.e4. doi: 10.1016/j.cgh.2020.03.018. Epub 2020 Mar 19. Clin Gastroenterol Hepatol. 2021. PMID: 32200087
• Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.

  Papamichael K, Cheifetz AS. Papamichael K, et al. Clin Gastroenterol Hepatol. 2021 Apr;19(4):854-855. doi: 10.1016/j.cgh.2020.04.088. Epub 2020 Nov 26. Clin Gastroenterol Hepatol. 2021. PMID: 33248082 No abstract available.